Quantum BioPharma Featured in CTV W5 Investigation on Alleged Market Manipulation

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) was featured in Part 2 of CTV News' investigative program W5's three-part series examining the company's allegations of stock spoofing. The segment, reported by award-winning journalist Jon Woodward, covers Quantum BioPharma's $700 million lawsuit against CIBC and RBC and the company's claims of widespread market manipulation. According to the company, this alleged activity has impacted its efforts to advance Lucid-MS, a potential treatment for multiple sclerosis.

CEO Zeeshan Saeed and Co-Executive Chair Anthony Durkacz reiterated their concerns about the alleged market manipulation during the W5 segment. They noted that Canadian exchange data cited in the lawsuit points to millions of purportedly illegal orders originating from bank platforms. The full press release detailing these allegations is available at https://ibn.fm/t3Tex.

Quantum BioPharma is a biopharmaceutical company focused on developing treatments for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary Lucid Psycheceuticals Inc., the company is advancing its lead compound Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. Myelin degradation is the underlying mechanism of multiple sclerosis, making this development potentially significant for patients with this chronic autoimmune disease.

The company also maintains a portfolio of strategic investments through its wholly owned subsidiary FSD Strategic Investments Inc., which represents loans secured by residential or commercial property. Additionally, Quantum BioPharma invented unbuzzd(TM) and spun out its OTC version to Unbuzzd Wellness Inc., retaining 20.11% ownership as of March 31, 2025. The agreement includes royalty payments of 7% of sales from unbuzzd(TM) until payments total $250 million, after which the royalty drops to 3% in perpetuity. The company retains 100% of the rights to develop similar products for pharmaceutical and medical uses.

The latest news and updates relating to Quantum BioPharma are available in the company's newsroom at https://ibn.fm/QNTM. The allegations of market manipulation highlighted in the CTV W5 investigation raise important questions about market integrity and its potential impact on biopharmaceutical companies seeking to develop treatments for serious medical conditions. If proven, such manipulation could affect investor confidence and potentially hinder funding for critical medical research and development efforts.

The outcome of Quantum BioPharma's lawsuit and the continued investigation by CTV W5 may have broader implications for market regulation and oversight in the biopharmaceutical sector. As companies like Quantum BioPharma work to advance treatments for conditions like multiple sclerosis, market stability and integrity become increasingly important for ensuring that promising medical research can proceed without unnecessary obstacles. The situation highlights the complex relationship between financial markets and medical innovation, where alleged market manipulation could potentially delay or disrupt the development of treatments that might benefit patients worldwide.